Cholinergic anti‐inflammatory pathway in the non‐obese diabetic mouse model

By  

ORAL DISEASES, Vol. 1354-523X, Iss. 7, 2015-10 ,pp. : 858-865

John Wiley & Sons Inc

Access to resources Recommend Favorite

The cholinergic anti‐inflammatory pathway revisited

By  

NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol. 30, Iss. 3, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recommendations for the use of the non‐obese diabetic/severe combined immunodeficiency mouse model in autoimmune and drug‐induced thrombocytopenia: communication from the SSC of the ISTH

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 5, 2015-05 ,pp. : 872-875

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reversible lacrimal gland‐protective regulatory T‐cell dysfunction underlies male‐specific autoimmune dacryoadenitis in the non‐obese diabetic mouse model of Sjögren syndrome

By  

IMMUNOLOGY, Vol. 145, Iss. 2, 2015-06 ,pp. : 232-241

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti‐oxidative effect of the β‐blocker carvedilol on diabetic nephropathy in non‐obese type 2 diabetic rats

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 9, 2015-09 ,pp. : 972-978

John Wiley & Sons Inc

Access to resources Recommend Favorite